<DOC>
	<DOCNO>NCT01387542</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety paliperidone extend release ( ER ) treatment Thai schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) participant .</brief_summary>
	<brief_title>Safety Efficacy Study Paliperidone Extended Release ( ER ) Among Thai Schizophrenia Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , non-randomized ( study drug assign chance ) study evaluate efficacy safety paliperidone ER adult Thai schizophrenia participant . The study consist screen phase open-label treatment phase . Study duration 10 week participant either inpatient outpatient . The recommended paliperidone ER start maintenance dose 6 milligram ( mg ) per day participant . Throughout study , flexible dose range 3 12 mg per day may use discretion investigator . Throughout study , participant evaluate efficacy use clinician rating ( Clinical Global Impressions-Severity [ CGI-S ] scale , Personal Social Performance Scale [ PSP ] ) scale . Safety participant monitor .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Meet Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criterion schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) Participants unsatisfied previous treatment Previously currently oral atypical antipsychotic Serious unstable medical condition , include recent present clinically relevant laboratory abnormality History current symptom tardive dyskinesia ( twitch jerk movement control face , tongue , part body ) History neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness ) Pregnant breastfeed female Participation investigational drug trial within 30 day prior selection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Extended Release ( ER )</keyword>
	<keyword>INVEGA</keyword>
</DOC>